(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.